

January 29, 2013

M. Laurent MEESCHAERT
28 rue Saint Lazare
75009 PARIS
FRANCE

Dear Mr. MEESCHAERT:

I am writing in response to your letter of January 7, 2013 to Dr. John Lechleiter, in which you requested authorization to post our previous correspondence on human embryonic stem cell research to your website (www.embryo-ethics.com).

Upon review of the website, we noted what we consider to be an error that may be due to a misunderstanding in our previous correspondence on October 20, 2011. If the purpose of your survey is to reflect current *practice*, as the wording on your homepage and table implies, then for clarification, Lilly has not and is not conducting research with human embryonic (or fetal) stem cells, nor do we have plans to do so. As stated in the October 2011 letter, we use stem cells from animals and human adults (e.g., bone marrow, fat, skin, and tumors), as well as umbilical cord blood. We're also pursuing research with induced pluripotent stem cells (iPS), whereby pluripotent stem cells can be derived from mature cells – like skin cells – obtained from adult human donors. Therefore the correct Lilly classification for your website should be “no research on human embryo stem cells”.

Regarding the company's *position* on this topic, as discussed in the October 2011 letter, Lilly believes the vast majority of its research and development goals that require the use of stem cell technology can and will be achieved without sources that destroy a human embryo. Consideration of embryonic stem cell research would be quite exceptional, and would require rigorous due diligence to confirm that the research addresses a compelling medical need and the scientific question cannot be answered adequately by an alternative method.

We have no objection to your request to post our letter from October 20, 2011, since our position on this matter is publicly available (www.Lilly.com). However, I am requesting that you also include this correspondence with your posting. I'm also requesting that you make the necessary correction to your table to accurately reflect the fact that Lilly has not and is not conducting human embryonic stem cell research.

Sincerely,

A handwritten signature in black ink, appearing to read "Donald G. Therasse". The signature is fluid and cursive, with a large initial "D" and "T".

Donald G. Therasse, MD

Vice President of Global Patient Safety and Bioethics